Skip to main content
Caplight Logo









Noetik

Noetik

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.noetik.ai/

Last Round

Grant

Mar 5, 2025

Total Funding Raised

$54.25M

Company Overview

Noetik is a biotechnology company that develops AI-driven platforms for cancer immunotherapy discovery and development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Subscription SaaS, Data as a Service, Services & Consulting

AI Layer

Foundation

Keywords

foundation modelsvirtual cell biologyAI drug discoverycancer research AIspatial oncologybiotech AIspatial biologypredictive biomarkersdrug discoveryAI-driven therapeuticsprecision medicineAI pathologyclinical trial optimizationin silico biologymultimodal spatial data

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Noetik Comparables

Compare Noetik with similar companies based on industry and business-model similarity.

Noetik comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tahoe Therapeutics
85%
Bioptimus
83%
GenBio AI
82%

Noetik Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 5, 2025
Series AAug 28, 2024
SeedSep 7, 2023

Key People

Founding team and executive leadership

Ron Alfa

Co-Founder CEO

Founding Team

FRCS Shafique Virani

Chief Business Officer

Executive Team

Noetik Investors

Notable investors and investment history

Noetik investors
InvestorRounds
Khosla VenturesSeries A
Zetta Venture PartnersSeries A, Seed
The Roddenberry FoundationGrant
Intermountain VenturesSeries A, Seed
Catalio Capital ManagementSeries A, Seed
EPIC VenturesSeries A, Seed
Breakout VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2025

    Partnering with Agenus to develop predictive biomarkers for immuno-oncology.

  • Apr 10, 2025

    Dr. Emily Corse appointed EVP of Therapeutics.

Recent news

Latest coverage and updates

  • has_revenueAug 10, 2026

    Noetik Inc. had revenue of $3.9M on Sep 1st '25.

Noetik Filings

Explore SEC and related filing metadata, where available.

Noetik filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Noetik's valuation, stock price, and market status.

Is Noetik a public or private company?

Noetik is a private company.

What is the current stock price of Noetik?

Noetik is a private company with no public stock price. No recent secondary market data is available.

How much is Noetik worth (valuation)?

Valuation information for Noetik is not publicly available.

Can I buy Noetik stock?

Noetik shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Noetik's last funding round?

Noetik's most recent funding round was Grant on March 5, 2025.

Who are the main investors in Noetik?

Key investors in Noetik include Polaris Partners.

Will Noetik IPO soon?

No public IPO plans have been announced for Noetik.

How can I track Noetik secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Noetik's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range41
Year Founded2022
Last FundingMar 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?